2019
DOI: 10.1038/s41374-018-0184-7
|View full text |Cite
|
Sign up to set email alerts
|

FOXO3 is involved in the tumor necrosis factor-driven inflammatory response in fibroblast-like synoviocytes

Abstract: Fibroblast-like synoviocytes (FLS) are major contributors to joint inflammation in rheumatoid arthritis (RA). Forkhead box O 3 (FOXO3) perturbations in immune cells are increasingly linked to RA pathogenesis. Here, we show that FOXO3 is distinctly inactivated/phosphorylated in the FLS of rheumatoid synovitis. In vitro, stimulation of FLS with tumor necrosis factor-alpha α (TNFα) induced a rapid and sustained inactivation of FOXO3. mRNA profiling revealed that the inactivation of FOXO3 is important for the sust… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
21
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 24 publications
(21 citation statements)
references
References 46 publications
0
21
0
Order By: Relevance
“…Thus, for example, early studies perhaps surprisingly reported that miR-155 plays a joint-protective role in RA SFs, having been associated with downregulation of MMP1 and MMP3, mediators that promote SF proliferation and invasion, as well as bone destruction 35, 36, 38, 39, 46 . However, although these studies also indicated that miR-155 did not impact on MMP9 or MMP13 expression or modulate spontaneous or stimulated (TLR ligands/cytokines) TGF β or IL-6 production 41, 47 , more recent work has identified a key role for this miR in driving (spontaneous and TNF α -stimulated) pathogenic responses (proliferation as well as IL-1 β and IL-6 production) via downregulation of its target FOXO3 4850 , which acts to suppress these functional outcomes in RA-SFs 51 . Thus, given the interactions of miR-155 with multiple TLR and cytokine (IL-1 β , IL-10, IL-17, TNF α , GM-CSF) pathways implicated in regulating arthritogenesis 38, 39 , we further investigated the role of this element in SF pathogenesis and ES-62-mediated protection.…”
Section: Resultsmentioning
confidence: 99%
“…Thus, for example, early studies perhaps surprisingly reported that miR-155 plays a joint-protective role in RA SFs, having been associated with downregulation of MMP1 and MMP3, mediators that promote SF proliferation and invasion, as well as bone destruction 35, 36, 38, 39, 46 . However, although these studies also indicated that miR-155 did not impact on MMP9 or MMP13 expression or modulate spontaneous or stimulated (TLR ligands/cytokines) TGF β or IL-6 production 41, 47 , more recent work has identified a key role for this miR in driving (spontaneous and TNF α -stimulated) pathogenic responses (proliferation as well as IL-1 β and IL-6 production) via downregulation of its target FOXO3 4850 , which acts to suppress these functional outcomes in RA-SFs 51 . Thus, given the interactions of miR-155 with multiple TLR and cytokine (IL-1 β , IL-10, IL-17, TNF α , GM-CSF) pathways implicated in regulating arthritogenesis 38, 39 , we further investigated the role of this element in SF pathogenesis and ES-62-mediated protection.…”
Section: Resultsmentioning
confidence: 99%
“…In immune cells, FOXO3 activity is critical for maintenance of immune progenitor cell homeostasis (3)(4)(5) and its deficiency in B and T cells leads to their enhanced activity during infection (6). A role of FOXO3 as a powerful immune break was discussed in several studies (7,8). In patients with inflammatory diseases such as rheumatoid arthritis and IBD, genome-wide association studies have shown that individuals with a single nucleotide polymorphism (SNP) in the FOXO3 gene locus leading to lowered FOXO3 expression have a more aggressive disease course (9, 10).…”
Section: Introductionmentioning
confidence: 99%
“…Different cytokines signal through different JAK combinations; blocking the JAKs can block the action of a number of cytokines directly or indirectly, including γ-chain cytokines, IL-1, IL-6, IL-7, IL-12, IL-15, IL-17, IL-22, IL-23, and TNF-α (Figure 4 ). As a result, JAK inhibitors are emerging therapies that are demonstrating efficacy for the treatment of inflammatory diseases that act through cytokine production[ 17 - 21 ].…”
Section: Discussionmentioning
confidence: 99%